SOBI Swedish Orphan Biovitrum AB (publ)

46.13USD467.80 SEK · STO-1.35%Mkt Cap: 16.05B USDP/E: 24.70

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates…

Institutional holders12 on file

Key Statistics

Company
Market Cap16.05B USD
Enterprise Value17.55B USD
Revenue (TTM)3.15B USD
Gross Profit2.17B USD
Net Income (TTM)47.14M USD
Revenue/Share9.10 USD
Last Price46.13 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.2K
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0000872095
Valuation
P/E (Trailing)24.70
P/E (Forward)30.08
PEG0.25
EV/EBITDA13.86
EV/Revenue5.57
P/S5.09
P/B3.58
EPS (TTM)1.87 USD
EPS (Forward)1.53 USD
52W Range
31.0080% of range50.00
52W High50.00 USD
52W Low31.00 USD
Profitability
Gross Margin77.86%
Oper. Margin30.87%
EBITDA Margin40.16%
Profit Margin1.69%
ROE1.27%
ROA0.71%
ROIC1.91%
ROCE1.79%
Growth
Revenue Growth17.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF844.59M USD
CapEx (TTM)310.92M USD
FCF Margin12.73%
FCF Yield2.50%
Net Debt1.49B USD
Net Debt/EBITDA1.18
Net Debt/FCF3.72
Balance Sheet
Debt/Equity0.30
Current Ratio0.99
Quick Ratio0.65
Book Value/Sh12.87 USD
Cash/Share0.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.95 USD
Upside (mean)+8.3%
Target Range30.37 USD – 59.17 USD
30.37+8.3% to mean59.17
# Analysts12
Ownership
Shares Out.348.00M
Float346.85M
Insiders10.09%
Institutions70.25%
Technical
SMA 5044.77 (+3.0%)
SMA 20043.05 (+7.1%)
Beta0.33
S&P 52W Chg12.00%
Avg Vol (30d)433.82K
Avg Vol (10d)541.87K
Technical Indicators
RSI (14)48.3
MACD5.8971
MACD Signal9.0536
MACD Hist.-3.1565
BB Upper49.59 USD
BB Middle47.25 USD
BB Lower44.91 USD
BB Width9.90%
ATR (14)1.221 USD
Vol Ratio (20d)3.41x

About Swedish Orphan Biovitrum (STO: SOBI)

›

Swedish Orphan Biovitrum (STO: SOBI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,207 employees.

The shares were at 467.80 SEK on 19 November 2026, up 37.5% over 52 weeks. Its 52-week range is 314.40 SEK to 507.00 SEK: the price is 7.7% below the high and 48.8% above the low.

At a market capitalisation of 162.80B SEK, it trades at 24.7 times trailing earnings and 30.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, so SOBI is valued in line with them.

Swedish Orphan Biovitrum reports return on equity of 1.3%, an operating margin of 30.9% and revenue up 17.3% year over year.

Its debt exceeds its cash by 15.15B SEK, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 506.50 SEK is 8.3% above the current price. The next earnings report is expected on 4 February 2027.